In contrast, another group that studied gene expression data sets reported reduced levels of RSPO3 in prostate tumors compared to healthy tissue, with further expression loss in metastatic disease and RSPO3 loss correlating with an increased risk of relapse [132]. The gene discussed is RSPO3; the disease is metastatic neoplasm.